Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
23,005.63
(
-2.16%
)
Dow Jones
45,960.11
(
-1.01%
)
Brent Oil
100.67
(
1.92%
)
Bitcoin
68,692.53
(
-3.66%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: north40000 post# 201450

Wednesday, 09/27/2017 7:19:39 PM

Wednesday, September 27, 2017 7:19:39 PM

Post# of 257295
Another CMC “gotcha”—Intarcia receives CRL for Exenatide implant:

http://www.prnewswire.com/news-releases/intarcia-provides-corporate-update-300527104.html

The Company received clear and constructive guidance from the Agency regarding manufacturing aspects of the CRL and is on a clear path to move forward.

Emphasis added.

Intarcia has been a high-profile private biotech company, having raised $225M in 2015 (#msg-113238024).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today